With Latest DEA and FDA Approvals, Medicinal Cannabis Technological Progress Reaching New Levels
Palm Beach, FL – (October 31, 2018) – Medicinal cannabis continues to perform at a high level as its adoption into mainstream markets continues. Canada and Several states in the United States are raking in hundreds of millions of dollars in tax revenues from the raging success of medicinal and recreational cannabis. According to Statista, […]
Scientus Pharma Provides Update on Buccal Cannabis Development Program
TORONTO, October 31, 2018 – HydRx Farms Ltd. (o/a Scientus Pharma) (“Scientus” or the “Company”), a biopharmaceutical company conducting research and product development for extracts and formulations related to medical cannabinoids and their derivatives, today provided an update on its collaboration with Generex Biotechnology Corporation (OTCQB:GNBT) (“Generex”), whereby the companies are co-developing products for the […]
BioSig Technologies Opens Business Office in Norwalk, CT
New Location to Serve as the Company’s East Coast Business and Operations Hub Santa Monica, CA, Oct. 31, 2018 – BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced that the Company opened […]
Australis Capital Invests in Body and Mind Inc’s Nevada and Ohio Expansion
LAS VEGAS, NV, Oct. 30, 2018 /PRNewswire/ – Australis Capital Inc. (CSE: AUSA) (“Australis” or the “Company”) is pleased to announce that the Company has entered into a definitive agreement (the “Investment Agreement”) with Body and Mind Inc. (CSE: BAMM, US OTC: BMMJ) (“BaM”) to purchase units and debentures of BaM. BaM is a publicly traded […]
Cannabis Ignores Wider Stock Market, Follows Its Own Path
New York NY – October 30, 2018 – Following a tumultuous month, cannabis continues to carve its own path rather than following the lead of other stocks. As the stock market plummeted earlier this month, cannabis companies stayed strong, buoyed up by legislative changes in Canada. The cannabis market appears set for continuing growth […]
Vanadium: The World’s Critical Element Fueling a Major Trade War
New York NY – October 30, 2018 – The move towards the adoption of electric vehicles (EV’s) along with solar and wind power generation has sparked interest in what could become the next super metal: vanadium. The United States doesn’t currently produce vanadium; however, United Battery Metals (OTC:UBMCF) (CSE:UBM) (FWB:0UL) (Profile) is in development of […]
LandStar Inc Announces HIPAA Compliant Platform For $8 Billion Medical Marijuana Market
RALEIGH, N.C., October 30, 2018 — LandStar, Inc. (OTCPK: LDSR) (“LandStar” or the “Company”), the parent company of Data443™ Risk Mitigation, Inc. (“Data443”), a leading data security and privacy company, will be offering a Personal Privacy Compliance service to support the medical marijuana industry anticipated to reach $8 billion in annual sales in the United […]
OPTEC International Introduces “OPTEC SHIELD” Platinum Plus Warranty For OPTEC Fuel Maximizer Products
CARLSBAD, Calif., Oct. 30, 2018 /PRNewswire/ — OPTEC International, Inc., (OTCQB: OPTI) today announced the introduction of the “OPTEC SHIELD” Platinum Plus warranty assurance as an inclusive re-insurance policy for additional protection with the OPTEC Fuel Maximizer products. OPTEC International, Inc., the exclusive worldwide distributor of the OPTEC Fuel Maximizer, will now include the “OPTEC SHIELD” warranty […]
Generex Biotechnology Announces IND Filing for a Phase II Clinical Trial of AE37 in Combination with Pembrolizumab (Keytruda®) for the Treatment of Triple-Negative Breast Cancer
MIRAMAR, Fla.- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the Company filed an investigational new drug application (IND) with the U.S. Food & Drug Administration (FDA) to initiate A Phase II Clinical Trial of Pembrolizumab (Keytruda®) in Combination with the AE37 Peptide Vaccine in Patients with Metastatic Triple Negative Breast Cancer. The trial, […]
Q BioMed Takes the Stage in the Expanded Access Debate at European Early and Managed Access Program Conference
Q BioMed Orphan Drug VP, who started the first Expanded Access Program Database asked to Speak on Panels and run Roundtable at the Early and Managed Access Program Conference in the UK from October 22nd to 24th 2018 NEW YORK, October 26, 2018 /PRNewswire/ — Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, […]